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The purpose of this study is to evaluate the survival of pediatric patients undergoing autologous bone marrow
transplantation (auBMT) for relapsed or refractory Hodgkin lymphoma (rrHL) and to identify factors that
might contribute to their outcome. We reviewed the records and clinical course of 89 consecutive rrHL pa-
tients  21 years old who underwent auBMT at Stanford Hospitals and Clinics and the Lucile Packard Chil-
dren’s Hospital, Stanford between 1989 and 2012. We investigated, by multiple analyses, patient, disease, and
treatment characteristics associated with outcome. Endpoints were 5-year overall and event-free survival.
Our ﬁndings include that cyclophosphamide, carmustine, and etoposide (CBV) as a conditioning regimen for
auBMT is effective for most patients  21 years old with rrHL (5-year overall survival, 71%). Transplantation
after the year 2001 was associated with signiﬁcantly improved overall survival compared with our earlier
experience (80% compared with 65%). Patients with multiply relapsed disease or with disease not responsive
to initial therapy fared less well compared with those with response to initial therapy or after ﬁrst relapse.
Administration of post-auBMT consolidative radiotherapy (cRT) also appears to contribute to improved sur-
vival. We are able to conclude that high-dose chemotherapy with CBV followed by auBMT is effective for the
treatment of rrHL in children and adolescents. Survival for patients who undergo auBMT for rrHL has
improved signiﬁcantly. This improvement may be because of patient selection and improvements in utili-
zation of radiotherapy rather than improvements in chemotherapy. Further investigation is needed to
describe the role of auBMT across the entire spectrum of patients with rrHL and to identify the most
appropriate preparative regimen with or without cRT therapy in the treatment of rrHL in young patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chemotherapy with radiation therapy cures most pedi-
atric patients with Hodgkin lymphoma (HL). As a result of
multidisciplinary risk-stratiﬁed therapy, young patients
diagnosed with HL have a 5-year survival rate approaching
90% [1,2]. Nevertheless, initial therapy is unsuccessful for 10%
to 15% of patients [3,4]. Treatment options for these patients
include salvage chemotherapy with or without radiotherapyedgments on page 334.
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ty for Blood and Marrow Transplantation.(RT) or high-dose chemotherapy followed by rescue with
autologous stem cell transplantation (auBMT). Attempts to
cure children with incompletely responsive or rapidly
relapsed disease (recurrence  12 months from end of
therapy) with salvage chemotherapy strategies that do not
include auBMT have been less successful, with reported
overall survival (OS) as low as 47% and event-free survival
(EFS) as low as 27% [5]. High-dose chemotherapy followed by
auBMT is effective therapy for patients with relapsed or
refractory HL (rrHL) and has become a standard approach for
such patients, with OS ranging from 43% to 95% [6-8].
AuBMT was ﬁrst demonstrated to be effective treatment
for adults with rrHL [9,10]. Similarly, studies have demon-
strated auBMT to be the treatment of choice for many
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to 95% [11-14]. In the management of both pediatric and
adult patients, the 2 most widely used chemotherapy-based
preparative regimens are carmustine (BCNU), etoposide,
cytarabine, and melphalan (BEAM) or cyclophosphamide,
carmustine, and etoposide (CBV) [15]. At our institution, we
have utilized several preparative regimens for auBMT,
including CBV along with RT before or after auBMT. We
previously published the results for childrenwho underwent
HSCT for rrHL between 1989 and 2001 and demonstrated
that more than one half of these patients can be treated
successfully with high-dose therapy followed by auBMT [14].
In this report, we have updated our results and evaluate
whether outcome for children with rrHL who undergo
auBMT has changed over time. We analyzed 89 consecutive
patients 21 years old or younger who underwent auBMT for
rrHL at Stanford Hospitals and Clinics and the Lucile Packard
Children’s Hospital, Stanford between 1988 and 2012.
PATIENTS AND METHODS
Study Design
We conducted a retrospective analysis of all patients 21 years old or
younger who underwent auBMT for rrHL at Stanford Hospitals and Clinics or
Lucile Packard Children’s Hospital, Stanford. Patients were treated with 1 of
several auBMT regimens available at our institution between September
1988 and April 2012. Although some patients were enrolled on clinical trials,
this report is not a clinical trial and participation in another clinical trial did
not affect the inclusion of their case information in the current study. All
patients had histologically conﬁrmed diagnosis of HL at initial presentation
and relapse. To be eligible for transplantation, patients had to have had
primary refractory HL (ie, never in remission), ﬁrst relapse had to have
occurred  12 months from the end of initial or salvage therapy, or patients
had to havemultiply relapsed disease. The goal of pre-auBMT therapy was to
achieve minimal residual disease using salvage therapy.
Eligibility requirements for auBMT also included adequate organ func-
tion including: adequate hematologic parameters (WBC > 3500/uL and
platelets > 100,000/uL unless there was biopsy-proven bone marrow
involvement), pulmonary function (diffusion capacity > 60%), cardiac
function (ejection fraction greater than 50%), hepatic function (serum bili-
rubin < 2 mg/100mL and aspartate transaminase and alanine transaminase
< 3  normal, unless there was radiographic or biopsy evidence of
involvement with HL), and renal function (serum creatinine < 1.5 mg/100
mL). Patients and/or their parents or guardians provided informed consent
for therapy and for long-term follow-up. The institutional review board
approved all clinical research protocols and data collection used in this
study.
Patients with rrHL ﬁrst received chemotherapy and/or RT to achieve
minimal disease burden before high-dose therapy. For patients registered on
a research protocol, the preparative regimen was determined by protocol.
For patients not enrolled on a research protocol, treatment regimen
depended upon physician preference among treatment regimens available
at the institution at the time. Patients were assessed for RT as consolidation
after auBMT depending on prior RT.
Conditioning regimens are listed in detail in Table 1 and include CBV;
cyclophoshamide, lomustine, and etoposide (CCV); fractionated total body
irradiation, cyclophosphamide, and etoposide (fTCV); CBV plus gemcitabine
(GVCBV); or in 2 cases, a different regimen. The use of fractionated totalTable 1
Preparative Regimens and the Number of Patients who Received Each
Regimen (n) Agent Agent Agent
CBV (51) BCNU (
Day 6
CCV (12) CCNU (
Day 6
fTCV (6) fTBI (12
Days 
GVCBV (17) Gemcitabine (1250 mg/m2)
Days 13 & 8
Vinorelbine (30 mg/m2)
Days 13 & 8
BCNU (
Day 6
Other (3)
CCV indicates cyclophosphamide, CCNU (lomustine), and etoposide; fTBI, fractiona
Radiation received as part of regimen 3 is separate from radiation therapy receivebody irradiation as part of the high-dose therapy regimenwas part of a small
institutional trial and patient participation in this trial was not based upon
disease severity.
Patients who underwent auBMT before 1997 did not receive con-
solidative RT (cRT). CRT was introduced gradually as institutional practice in
the late 1990s and became standard of care by 2001. After 2001, all patients
who received auBMT also were treated with cRT as allowed by tissue
tolerance. Patients who already received tissue maximal doses did not
receive cRT. Patients who had received reduced-dose RT during up-front
therapy received cRT up to maximal tissue tolerance or 25 Gy. Thus, pre-
cise dosing varied from patient to patient but typically ranged from 5 to 25
Gy in 1.5 Gy fractions to relapsed nodal sites when sufﬁcient recovery of
blood counts permitted RT.Tumor Response Evaluation
Patients were classiﬁed by response to upfront induction therapy as
follows:
Complete response (CR) was deﬁned as no evidence of tumor by clinical,
or biochemical evaluation and no more than minimal disease by, radio-
graphic evaluation by 30 days after completion of primary or salvage ther-
apy (ie, second CR, third CR) [14,16,17].
Partial response (PR) was deﬁned as persistence of tumor by clinical,
biochemical, or radiographic evaluation by 30 days after therapy without
further worsening of the disease [14,18].
Induction failure (IF) was deﬁned as disease that progressed during
initial therapy or attained only transient (<60 days) response, respectively
[14,18].
We deﬁned relapsed disease as histologically proven disease recurrence
 60 days after successful primary treatment. We did not consider stage or
disease extent at transplantation in our study.
We categorized patients by disease status at the time of transplantation
into 3 groups according to response to treatment and number of relapses:
those who never entered remission (IF or PR), those who underwent
transplantation after ﬁrst relapse (second CR or PR or failure of reinduction/
salvage therapy), and those who underwent transplantation after 2 or more
relapses (third CR or PR).
Restaging studies (CBC, complete metabolic panel, chest x-ray,
computed tomography scans [CT], and for some patients positron emission
tomography [PET]) were obtained between day þ30 and day þ60 after
transplantation.
Routine follow-up studies including regular labs, chest radiography,
tomography, and nuclear medicine studies were repeated at least every 3 to
6 months for 2 years and then annually unless disease-related signs or
symptoms recurred.Statistical Methods
OSwas deﬁned as the date from stem cell infusion until the date of death
from any cause.
EFS was calculated as the time from date of stem cell infusion until the
date of an adverse event, including relapse or progression of HL, develop-
ment of a secondary malignancy, or death from any cause. When patients
sufferedmore than 1 event, the time to the ﬁrst eventwas used to determine
the EFS.
Lifetables were constructed using the method of Kaplan and Meier [19].
Patients not suffering adverse events were censored at the time of last
follow-up.
Treatment-related mortality (TRM) was deﬁned as death within 100 days
of the date of stem cell infusion, excluding those deaths due to relapsed
disease.Agent Agent
10-15 mg/kg) Etoposide (60 mg/kg)
Day 4
Cyclophosphamide (100 mg/kg)
Day 2
6 mg/kg) Etoposide (60 mg/kg)
Day 4
Cyclophosphamide (100 mg/kg)
Day 2
gy)
8 to 5
Etoposide (60 mg/kg)
Day 4
Cyclophosphamide (100 mg/kg)
Day 2
10 mg/kg) Etoposide (60 mg/kg)
Day 4
Cyclophosphamide (100 mg/kg)
Day 2
ted total body irradiation.
d as initial therapy not associated with auBMT.
Table 2
Study Characteristics
Patients n
Total 89
Male 50
Female 39
Age, average (range), yr 17.8 (8-21)
Follow-up
Average (range), d 2287 (13-7646)
Average (range), yr 3.25 (.03-21)
Transplantations per year, average (range) 3.56 (1-9)
Stem cell source
Bone marrow 19
Peripheral blood 70
Status at transplantation
IF 7
PR 16
Second CR/PR/IF 46
>Second PR 9
Disease status at the time of transplantation was known for 78 of 89 pa-
tients.
Second CR/PR/IF refers to patients who had a complete response, partial
response, or no response after reinduction (salvage) therapy after ﬁrst
relapse.
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moment correlation analyses were used to explore variables that might
account for changes in survival.
Data were stored in a protected Research Electronic Data capture
database [20]. Statistical analyses were performed using the Software
Package for Social Sciences (SPSS) Statistics (IBM, Armonk, NY) and Graph-
Pad Prism (GraphPad Software, La Jolla, CA).
RESULTS
Patient Characteristics
Patient characteristics are listed in Table 2. Before auBMT,
all patients received conventional risk-adjusted multiagent
chemotherapy. Salvage therapy was used to attempt to re-
establish remission before auBMT. All but 7 patients had
disease that responded to initial induction therapy (n ¼ 82).
Median follow-upwas 4.4 years (range, 0 to 21 years).We did
not have enough data to stratify patient risk before trans-
plantation, as suggested by other studies [21].
Outcome
Figure 1A displays survival probability for our entire
cohort. Estimated 5-year OSwas 71% and 5-year EFSwas 65%.
Thirty-one patients suffered adverse events within 5 years
from the date of stem cell infusion (35%). Events included
relapse (n ¼ 22, 25%), secondary malignancy (n ¼ 2, 2%), and
nonmalignancy-related deaths (n ¼ 9, 8%). Of those who
developed and died from a secondary malignancy, 1 devel-
oped acute myeloid leukemia and the other developed
gastrointestinal adenocarcinoma, both potentially treatment
related. Twenty-three patients died within 5 years of trans-
plantation: 12 from disease relapse, 5 from pulmonary
complications, 2 from cardiac failure, 2 from a second ma-
lignancy, 1 from sepsis, and 1 after an accident (Figure 1B).
Patterns of Failure
Disease recurrence accounted for the greatest number of
deaths. In the entire cohort, 16 patients died as a result of
relapsed disease; 12 within 5 years of stem cell infusion. Two
of the 4 patients who died more than 5 years after stem cell
infusion relapsed within 1 year of stem cell infusion but
survived for several years. The other 2 suffered late rela-
psesdone 4 years after auBMT and the other 7 years after
auBMT.Five patients died within the ﬁrst 100 days after trans-
plantation and were classiﬁed as TRM. All of these patients
died before 2002. Three of these deaths were due to pul-
monary failure (acute respiratory distress syndrome or
interstitial pneumonitis) and 2 were due to cardiac failure.
Three of these patients received RT before auBMT (2 as cRT
more than 1 year before auBMT and 1 as fractionated total
body irradiation [fTBI] conditioning). RT data for the other 2
patients were not available. All deaths due to respiratory
causes occurred before 2002.
Effect of Year of Transplantation on Survival
ANOVA and Pearson product moment correlation ana-
lyses were performed to determine factors associated with
survival (Table 3). Only time of transplantation (before 2002
or 2002 to 2012) correlated with signiﬁcant changes in sur-
vival probability (P ¼ .04). Actuarial 5-year OS for patients
who underwent auBMT between 1988 through 2001 was
65% compared with 80% for those who underwent trans-
plantation from 2002 to 2012 (hazard ratio, 1.8; P ¼ .04)
(Figure 2A). Five-year EFS was 63% for patients who under-
went their transplantation between 1988 and 2001 and 72%
for those treated between 2002 and 2012 (hazard ratio, 1.7;
P ¼ .15) (Figure 2B). Median follow-up for patients from the
earlier era (1989 to 2001) was 7.7 years (range, .04 to 21
years) and from the later era (2002 to 2012) was 3.1 years
(range, .03 to 10.2 years). There was no effect of year of
transplantation on time to hematologic engraftment.
Effect of Conditioning Regimen on Survival
We investigated the impact of conditioning regimen on 5-
year survival (Figure 3). Five-year OS differed signiﬁcantly by
regimen (P ¼ .007). CBV was associated with the most
favorable outcomes, with a 5-year OS of 75% and EFS of 67%.
FTCV yielded the worst 5-year OS of 50% with an EFS of only
33%. We analyzed CCV; GVCBV; and the other regimens as a
group that consisted of 30 patients. This group had an in-
termediate 5-year OS of 67% and EFS of 60% but also had a
greater incidence of late deaths (5 years from trans-
plantation) than the other groups. Only 4 of 26 patients who
received CBV died more than 5 years after transplantation
(15%); 5 of 14 patients who received the non-CBV/non-fTCV
group and survived more than 5 years from transplantation
died (36%). Of these deaths, 2 were of unknown causes and 1
each was due to disease relapse, respiratory failure, or motor
vehicle collision.
We next investigated whether changes in regimen utili-
zation could account for the improved survival seen in the
group undergoing transplantation after 2001. CBV use was
relatively evenly distributed between the 2 eras. Fifty-one
patients received CBV. Of these, 28 did so before 2002
(55%) and 23 did so between 2002 and 2012 (45%). GVCBV
was only used after 2002. The remaining regimens were only
used before 2002.
There was no statistically signiﬁcant change in outcomes
for patients who received CBV before or after 2001. Patients
who received CBV before 2002 had a 5-year OS of 71% and 5-
year EFS of 66%, whereas patients who underwent auBMT
with CBV conditioning after between 2002 and 2012 had
improved 5-year OS: 82% (P¼ .21; hazard ratio, .5) and EFS of
73% (P ¼ .22).
Effect of Post-auBMT cRT on Outcome
Information on RT that was not part of the auBMT
regimen was available for 53 patients. This includes patients
Figure 1. Patient overall survival. (A) Kaplan-Meier estimates of overall (solid) and event free (dotted line) survival probability for all patients in the study. (B)
Outcomes for patients who underwent auBMT for rrHL. TRM indicates treatment-related mortality; MVC, motor vehicle collision; Infx, infection. Shaded boxes
represent patients who died.
P.M. Garﬁn et al. / Biol Blood Marrow Transplant 21 (2015) 326e334 329who received RT before transplantation to control their dis-
ease as well as those who received RT after their trans-
plantation as cRT. The remaining patients had their RT at
other institutions. Thirty-ﬁve of the 53 patients received cRT
within 3 months after their auBMT (median, 52 days; range,
26 to 87). Five-year OS for these patients was 82%; EFS was
77%. By comparison, the 5-year OS and EFS probabilities forTable 3
ANOVA and Correlation Analyses
Variable ANOVA F-Value
(P Value)
Pearson Correlation
(P Value)
Before 2001 10.386 (.001) .333 (.001)
Transplantation, yr 3.85 (.028) .402 (<.001)
Age at transplantation .171 (.171) .044 (.681)
Sex .056 (.056) .025 (.814)
Conditioning regimen .122 (.122) .037 (.728)
Values for ANOVA are reported as F-value followed in parentheses by P
value. Correlations are determined by the method of Pearson and P values
follow in parentheses. Signiﬁcant values are in italics. P values reported here
may differ than those in text as these are determined by ANOVA or Corre-
lation rather than survival curve comparison, which is the method reported
in the text.18 patients who did not receive post-auBMT cRT were 65%
and 61%, respectively. Although this difference in survival is
striking, it did not reach statistical signiﬁcance (P ¼ .15).
Twenty-ﬁve patients who received post-auBMT cRT under-
went auBMT after 2001 (71%). Only 39% (7 of 18) of the pa-
tients who did not receive post-auBMT cRT did so after 2001.
It remains to be seenwhat the longer-term survival might be
for patients who received post-auBMT cRT.Effect of Disease Status at the Time of auBMT
To investigate the impact of disease status at the time of
auBMT on outcome, we investigated outcomes for the 78
patients for whom disease status was known. Twenty-three
patients went underwent auBMT without ever entering
remission, 46 after ﬁrst relapse (second CR, PR, or IF; the
distribution of second CR, PR, and IF was consistent across
the 2 eras of patients), and the remaining 9 did so after 2 or
more relapses (third or greater CR or PR; only 2 of the 9
occurred after 2001) (Figure 4).
Patients who received auBMT after their ﬁrst relapse or
without ever entering remission had similar outcomes with a
5-year OS and EFS of 75% for those after ﬁrst relapse and 74%
Figure 2. Five-year overall survival by era. (A) Kaplan-Meier estimates of OS probability for patients who underwent transplantation between 1989 and 2001 (solid
line) and patients who underwent transplantation in 2002 or later (dotted line). Dotted vertical line indicates 5 years from date of transplantation. At 5 years after
transplantation, the difference in OS is signiﬁcant (P ¼ .04). (B) Kaplan-Meier estimates of EFS probability for patients who underwent transplantation between 1989
and 2001 (solid line) and patients who underwent transplantation in 2002 or later (dotted line). Dotted vertical line indicates 5 years from date of transplantation. At
5 years after transplantation, the difference in EFS is not signiﬁcant (P ¼ .15). The tables below the graphs show the number of patients at risk at yearly intervals after
auBMT.
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multiple relapses before undergoing auBMT fared the worst,
with 5-year OS and EFS of 51%.
Before 2002, 6 patients underwent auBMT without ever
having their disease in remission. All these patients were
classiﬁed as having suffered IF. Twenty other patients
underwent auBMT after 1 relapse and 7 of 9 patients who
underwent auBMTaftermultiple relapses did so before 2002.
After 2001, 17 patients underwent auBMT without
achieving remission. All but 1 of these 17 of these patients’
disease partially responded to upfront therapy. Twenty-six ofthe 46 patients who received auBMT after ﬁrst relapse did so
before 2002. Only 2 of the 9 patients who received their
auBMT after multiple relapses did so between 2002 and 2012.
Other factors, such as treating service, stem cell product
(marrow or blood), age, gender, and time to engraftment did
not affect survival.
DISCUSSION
Combined modality therapy is effective for the majority
of children and young adults with HL; nevertheless, 10% to
15% either suffer a relapse or fail to respond to initial
Figure 3. Five-year OS by regimen. (A) Kaplan-Meier estimates of OS probability for patients who received CBV (solid line), fTCV (dotted line), or other regimens
(dashed line) as high-dose therapy before auBMT 5 years from date of transplantation. At 5 years after transplantation, the difference in OS is signiﬁcant (P ¼ .007). (B)
Kaplan-Meier estimates of EFS probability for patients who received CBV (solid line), fTCV (dotted line), or other regimens (dashed line) as high-dose therapy before
auBMT 5 years from date of transplantation. At 5 years after transplantation, the difference in EFS is not signiﬁcant (P ¼ .16). The tables below the graphs show the
number of patients at risk at yearly intervals after auBMT.
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cacy of auBMT for most patients with rrHL [6,10-12,22].
Although direct clinical trial comparison data are lacking,
the collective experience is that outcomes for patients with
rrHL are best if these patients undergo auBMTas opposed to
non-auBMT regimens [6-8,10]. For example, in 1 study of
adult patients that directly compared salvage chemo-
therapy to high-dose chemotherapywith auBMT, those who
received auBMT had an EFS almost twice as high as thosethat did not receive auBMT (53% compared with 27%) and
also had increased OS (54% compared with 47%) [5].
Although the focus of our analysis is on 5-year survival,
many patients live for decades after auBMT for rrHL. Ob-
servations from our institutional experience suggest that
some children who relapse after auBMT survive for several
years after auBMT, conﬁrming the importance of long-term
follow up after auBMT to survey for and treat long-term
complications or very late relapses [22].
Figure 4. Five-year survival by disease status. (A) Kaplan-Meier estimates of OS probability for patients who underwent auBMT without ever having reached
remission (solid line), in second remission (dotted line), or after 3 or more remissions (dashed line). At 5 years after transplantation, the difference in OS is not
signiﬁcant (P ¼ .45). (B) Kaplan-Meier estimates of EFS probability for patients who underwent auBMT without ever having reached remission (solid line), in second
remission (dotted line), or after 3 or more remissions (dashed line). At 5 years after transplantation, the difference in EFS is not signiﬁcant (P ¼ .38). The tables below
the graphs show the number of patients at risk at yearly intervals after auBMT.
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high-dose therapy before auBMT in the setting of rrHL [14].
We update these ﬁndings, demonstrating again that CBV
conditioning has a high likelihood of establishing a stable
remission and prolonged survival for many children. A recent
study by William et al. [15] found that adults (median age,
33) with relapsed HL who received BEAM have signiﬁcantly
longer survival than those who received CBV with an OS of95% for those who received BEAM and 87% for those who
received CBV. This study included many patients much older
than even the oldest patients in our study and, thus, out-
comes may be different. We found no similar studies in the
pediatric age group. Certainly these 2 conditioning regimens
have different toxicity proﬁles and even though some of the
chemotherapy agents, such as melphalan, are considered to
have relatively low toxicity, even melphalan can cause
P.M. Garﬁn et al. / Biol Blood Marrow Transplant 21 (2015) 326e334 333signiﬁcant mucositis and has been associated with fatal
cardiac events [23-25]. Thus, if CBV results in similar
outcome to BEAMwith reduced acute and long-term toxicity,
it seems reasonable to compare these regimens directly in a
controlled trial.
We were unable to ﬁnd speciﬁc patient characteristics
associated with highest survival. Many of the factors that are
often associated with differences in survival expectancy for
patients with a variety of cancers (eg, age, or gender) did not
correlate with improved survival. Only the year of trans-
plantation correlated signiﬁcantly with outcome in our
study; those who received their transplants after 2001 had
improved OS compared with those who received their
transplant before 2002 (80% versus 65%).
Three factors appear to account for the improvement in
survival in our later cohort: decreased TRM, increased use of
post-auBMT cRT, and improved selection of patients for
auBMT. First, TRM decreased markedly after 2002. Although
5 patients died within the ﬁrst 100 days of transplantation
before 2002, from 2002 to 2012 there were no cases of TRM.
Some of this decrease in TRM may be because of improve-
ment in supportive care or in RT utilization, or because of
changes in patient selection practices. Another factor that
may contribute to the decrease in TRM, and perhaps also to
overall improved outcomes, is that in efforts to decrease
toxicity in more recent years, patients might have received
less therapy before BMTand, thus, may be in a better position
to respond to and to survive auBMT [26]. For example, some
patients in the more recent cohort may have received less
bleomycin than they would have in previous years and thus
contributed to the decrease in pulmonary events seen in the
more recently treated patients.
Second, our institutional practice has been to treat newly
diagnosed HL patients with chemotherapy and low-dose RT,
meaning that many patients whose disease relapses may be
able to tolerate additional RT. Beginning in the mid-1990s,
we began to provide additional post-auBMT cRT. It became
our standard practice to treat patients, when possible, with
post-auBMT RT. Although there are not enough comparators
to achieve signiﬁcance, increased use of post-auBMT RT
certainly trends with improved survival after auBMT. Our
changes in RT utilization may be an important contribution
to improved survival after auBMT for rrHL with both
decreased toxicity compared with use of RT as part of the
preparative regimen and possibly also increased efﬁcacy
compared to chemotherapy alone. In addition, improved and
increased use of PET-CT may have helped to guide RT both as
part of upfront therapy and also as consolidative therapy.
Thus, although post-auBMT RT seems to have an improved
survival after auBMT, our results did not reach statistical
signiﬁcance and lack longer term follow-up. Thus, a dedi-
cated trial studying the role of post-auBMT RT is necessary to
determine whether post-auBMT RT improves outcomes.
Third, patient selection practices appear to have changed
during the study period. Before 2002, 6 patients underwent
transplantation after induction failure, but after 2001, only 1
patient did so. Similarly, although 7 patients received their
auBMT in third or greater remission before 2002, only 2 did
so after 2001. Improvements in disease detection and ﬁne
tuning of diagnosis and initial therapymay enable physicians
to better risk stratify patients and evaluate treatment
response, improving initial therapy and better indicating
which patients are best suited to undergo auBMT for their
rrHL [2,27,28]. An important factor in determining which
patients are most suited for transplantation is disease statusas detected by PET-CT. Those patients with positive PET-CT
before auBMT are at much higher risk of having therapy
failure [21]. With the more active use of PET-CT to evaluate
disease responsiveness and the historically poor outcome for
patients with chemo-resistant disease, in the recent cohort
we performed transplantations in fewer patients with
chemo-resistant disease. This selection bias may be an
important factor in the different outcomes of autologous
BMT from different eras.
In addition, between 1988 and 2001, 7 patients under-
went auBMT after multiple relapses of their HL. Only 2 pa-
tients with multiply relapsed HL underwent auBMT after
2001. As this group had the least favorable outcomes, the
shift away from subjecting patients with multiply relapsed
HL to the rigors of auBMT likely also contributes to the
improved outcome in more recent years. In addition, the
relatively poor outcome for these patients also argues that it
is preferable to refer patients for auBMT after ﬁrst relapse.
Even though there is improved outcome for those patients
who undergo auBMT after relapse, it is important to recog-
nize that there is no role for auBMT as a primary therapy for
patients with high-risk HL [29]. Thus, auBMT should be used
to treat chemo-sensitive relapsed or recurrent pediatric HL
rather than primary disease or chemo-resistant disease.
Our data reﬂect increased understanding of the risks and
beneﬁts of auBMT for rrHL. For example, patients with a
strong history of atopy have a signiﬁcant increase in
pulmonary complications with auBMT [13]. This experience
may have subtly affected our treatment decisions for
atopic patients, potentially decreasing TRM for those
who undergo auBMT for their rrHL. In addition, improved
understanding of the risks and beneﬁts of using granulocyte
colonyestimulating factor after auBMT may have altered
outcomes. Similarly, our improved understanding of the
contribution of disease status to post-auBMT outcome may
have ledus tobemoreselective in thepatientswhowesubject
to auBMT. Indeed,most trials in this ﬁeld are selective in their
inclusion criteria [10]. Because we have reported only those
pediatric patients who underwent transplantation and not
those patients with rrHL who did not receive auBMT, we can
not fully describe the importance of auBMT for rrHL. Similarly,
we did not have data on salvage regimens before auBMT, so
we cannot evaluate the effects that different salvage therapy
regimens might have on outcomes, nor can we evaluate
alternative hypotheses explaining the improvements in sur-
vival for those who underwent auBMT for rrHL.
Similar limitations pertain to other reports of auBMT for
rrHL. Most studies of transplantation for rrHL capture only
patients who undergo the procedure and exclude patients
with rrHL who do not undergo auBMT. To best clarify the role
of and outcomes for auBMT with or without additional RT in
the treatment of rrHL, it is important to capture all patients at
the time of diagnosis of HL and continue to follow them
throughout therapy, whether or not they undergo auBMT.
Ideally, such a study would include a comparison of BEAM
with CBV. Such a study would help to identify patients best
suited for auBMT, identify prognostic factors for TRM and
EFS, and elucidate the optimal therapy.
In summary, we found improved outcomes for pediatric
patients who underwent auBMT for rrHL after 2001
compared to those who received auBMT in the prior era. An
international collaboration has investigated the problem of
relapse after auBMT for rrHL and agrees that there is room to
improve our treatment of rrHL [30]. Some new agents, such
as brentuximab vedotin, have emerged and are being used in
P.M. Garﬁn et al. / Biol Blood Marrow Transplant 21 (2015) 326e334334conjunction with stem cell transplantation in adults [31,32].
Early trials have been promising and demonstrate improved
outcome for some patients with rrHL [27]. Incorporation of
brentuximab vedotin and other new agents into HL treat-
ment schemas could improve EFS and decrease long-term
effects of therapy for rrHL. In the meantime, auBMT con-
tinues to be effective salvage therapy for the treatment of HL
in pediatric patients with rrHL.
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